BDSX (Biodesix) Current Deferred Revenue: $0.2 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BDSX Biodesix Inc BDSX
53 GF Score
Price $22.34
GF Value $21.33
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Biodesix Current Deferred Revenue?

Biodesix BDSX -4.73% 53 Current Deferred Revenue is $0.2 Mil as of Jun. 2026. GuruFocus rates BDSX with a GF Score™ of 53/100 and a GF Value™ of $21.33 (Fairly Valued). The stock has 5 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Biodesix's current deferred revenue for the quarter that ended in Jun. 2026 was $0.2 Mil.

Biodesix Current Deferred Revenue Related Terms

Biodesix Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Biodesix's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biodesix Current Deferred Revenue Chart

Biodesix Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial 1.85 0.96 0.32 0.68 0.96

Biodesix Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.62 2.77 0.96 0.22 0.21
BDSX
53GF Score
Biodesix Inc BDSX
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of $0.2 Mil mean?
Biodesix (BDSX) has a Current Deferred Revenue of $0.2 Mil as of Jun. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Biodesix and its competitors.
Is Biodesix's Current Deferred Revenue too high?
Biodesix's current Current Deferred Revenue is $0.2 Mil. Overall, Biodesix has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biodesix's Current Deferred Revenue compare to IMDX and XGN?
Biodesix's Current Deferred Revenue of $0.2 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Medical Diagnostics & Research company?
A good Current Deferred Revenue depends on the Medical Diagnostics & Research industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Biodesix and its competitors. Biodesix's current Current Deferred Revenue is $0.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biodesix stock overvalued right now?
Based on GuruFocus' analysis, Biodesix (BDSX) is currently considered Fairly Valued. The stock's GF Value™ is $21.33, compared to a current price of $22.34 — trading 4.7% above its estimated fair value. The current Current Deferred Revenue is $0.2 Mil. Biodesix's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Biodesix (BDSX), the current Current Deferred Revenue is $0.2 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biodesix (BDSX) Overvalued in 2026?

Based on GuruFocus' analysis, Biodesix stock appears to be overvalued. The current stock price of $22.34 is trading 4.7% above its estimated GF Value™ of $21.33. GuruFocus considers Biodesix to be Fairly Valued.

Key valuation signals for BDSX:

  • Current Deferred Revenue: $0.2 Mil
  • GF Value™: $21.33 vs. price of $22.34 (4.7% above fair value)
  • GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the BDSX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biodesix Business Description

Address 919 West Dillon Road, Louisville, CO, USA, 80027
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.
53GF Score

Get the complete analysis for BDSX

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.34
Price
$21.33
GF Value